# US 2004/0083003 A1 · Biologic modular tibial and femoral component augments for use with total knee arthroplasty

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0083003 A1
- Document ID: US20040083003A1
- Status: Published application
- Kind: A1
- Application number: 10/612,079
- Filed: 2003-07-02
- Published: 2004-04-29
- Earliest claimed: 2002-10-23
- Inventors: Ray C. Wasielewski
- Web page: https://patentgrep.com/patent/US20040083003A1

## CPC

- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61F 2/3886: {for stabilising knees against anterior or lateral dislocations}
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/3629: {Intestinal tissue, e.g. small intestinal submucosa}
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/3645: {Connective tissue}
- A61L 27/3843: {Connective tissue}
- A61L 27/58: Materials at least partially resorbable by the body
- A61F 2/3859: {Femoral components}
- A61F 2/389: {Tibial components (A61F2/3868 takes precedence)}
- A61F 2002/30064: {Coating or prosthesis-covering structure made of biodegradable material}
- A61F 2002/305: {Snap connection}
- A61F 2002/30518: {with possibility of relative movement between the prosthetic parts}
- A61F 2002/30672: {temporary}
- A61F 2002/30808: {parallel}
- A61F 2002/30919: {Sleeves}
- A61F 2220/0025: Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F 2310/00976: Coating or prosthesis-covering structure made of proteins or of polypeptides, e.g. of bone morphogenic proteins BMP or of transforming growth factors TGF
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

The use of biologic and/or biologically reabsorbable materials to provide temporary stability after a surgical joint procedure is provided. Exemplary embodiments of the invention provide biologic and/or biologically reabsorbable cam and/or post linings mounted to respective knee prosthesis components. Such linings are reabsorbed after a time sufficient for patient tissue formation to provide permanent stability. Likewise, the invention has application in any joint reconstruction where the integrity of the stabilizing tissue has been compromised by injury or as a result of the surgical procedure itself. Further aspects of the present invention include using biologic and/or biologically reabsorbable materials loaded with agents that may promote tissue formation, fight infection, and promote clotting. Still further aspects of the present invention are directed to the use of biologically reabsorbable snaps or other fasteners to attach a lining to the femoral component and/or the tibial component.

## Claims

### Claim 1

A prosthetic stabilizing device for use with a knee replacement prosthesis that includes a tibial component adapted to be mounted to a patient's tibia and a femoral component adapted to be mounted to the patient's femur, where the tibial component interfaces with the femoral component to simulate the biomechanics of a knee joint, the stabilizing device comprising:
a lining adapted to be mounted to at least one of a tibial component of a knee replacement prosthesis and a femoral component of the knee replacement prosthesis so that the lining is positioned between the tibial component and the femoral component approximate a prosthetic intercondylar channel of the femoral component to supplement periarticular stability between the tibial component and the femoral component;
the lining being comprised of a lining material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 2 (depends on 1)

The prosthetic stabilizing device of claim 1, further comprising at least one fastener for mounting the lining to the at least one of the tibial component and the femoral component, wherein the fasteners are comprised of a fastener material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 3 (depends on 2)

The prosthetic stabilizing device of claim 2, wherein the fastener material includes at least one, or an equivalent, of:
a poly-L-lactic acid material; and
collagen.

### Claim 4 (depends on 2)

The prosthetic stabilizing device of claim 2, wherein the fasteners are taken from a group consisting of:
screws;
snaps;
clips;
keyways; and
rivets.

### Claim 5 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining material includes at least one, or an equivalent, of:
extra cellular matrices (ECMs);
poliglecaprone 25;
polydioxanone;
surgical gut suture (SGS);
gut;
polyglactin 910;
human autograft tendon material;
collagen fiber;
poly-L-lactic acid (PLLA);
polylactic acid (PLA);
polylactides (Pla);
racemic form of polylactide (D,L-Pla);
poly(L-lactide-co-D,L-lactide);
polyglycolides (PGa);
polyglycolic acid (PGA);
polycaprolactone (PCL);
polydioxanone (PDS);
polyhydroxyacids; and
resorbable plate material.

### Claim 6 (depends on 5)

The prosthetic stabilizing device of claim 5, wherein the extra cellular matrices (ECMs) includes at least one, or an equivalent, of:
porcine small intestine submucosa (SIS);
xenogeneic small intestine submucosa (xSIS);
urinary bladder submucosa (UBS);
laminated intestinal submucosa; and
glutaraldehyde-treated bovine pericardium (GLBP).

### Claim 7 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining material is adapted to be substantially absorbed by a patient's body after implantation and to be substantially replaced by the patient's tissue.

### Claim 8 (depends on 7)

The prosthetic stabilizing device of claim 7, wherein the lining material is adapted to be substantially absorbed and replaced by the patient's tissue within approximately 6 months after implantation.

### Claim 9 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein at least one surface of the lining approximates a contour of a surface of at least one of the tibial component and the femoral component to which the lining is mounted.

### Claim 10 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein at least a portion of the lining is adaptable to the shape of the at least one of the tibial component and the femoral component to which the lining is mounted.

### Claim 11 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining is mounted to the tibial component and includes an outer surface that approximates a contour of a surface of the femoral component most likely coming into contact therewith.

### Claim 12 (depends on 11)

The prosthetic stabilizing device of claim 11, wherein the contour of the femoral component approximates an inner surface of at least one of a prosthetic medial condyle element and a prosthetic lateral condyle element partially defining the prosthetic intercondylar channel.

### Claim 13 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining is mounted to the femoral component and includes an outer surface that approximates a contour of a surface of the tibial component passing into the prosthetic intercondylar channel.

### Claim 14 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining material is loaded with at least one of a tissue promotion agent, a clotting agent, and an antibiotic agent.

### Claim 15 (depends on 14)

The prosthetic stabilizing device of claim 14, wherein the lining material is loaded with a clotting agent that includes concentrated platelets.

### Claim 16 (depends on 14)

The prosthetic stabilizing device of claim 14, wherein the lining material is loaded with an antibiotic agent that includes gentamicin.

### Claim 17 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein:
the tibial component includes a stabilizing post at its proximal end adapted to be received within the intercondylar channel of the femoral component; and
the lining is adapted to be mounted to at least one of the stabilizing post and a surface of the intercondylar channel.

### Claim 18 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining material is loaded with at least one of connective tissue stem cells and connective tissue stem cell progenitors.

### Claim 19 (depends on 18)

The prosthetic stabilizing device of claim 18, wherein the connective tissue stem cells and connective tissue stem progenitors are taken from the group consisting of: fibroblastic colony-forming cells, fibroplast colony-forming units (CFU-F), bone marrow stromal cells, mesenchymal stem cells (MSC), and vascular pericytes.

### Claim 20 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining material is loaded with a growth stimulating factor.

### Claim 21 (depends on 20)

The prosthetic stabilizing device of claim 20, wherein the growth stimulating factor is taken from the group consisting of: growth factor beta (GFB-β), basic fibroblast growth factor (bFGF), fibroblast growth factor (FGF), epidermal growth factor (EFG), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), direct-mediated gene transfer, fibroblast-mediated gene transfer, myoblast-mediated gene transfer, TGF-β gene family, adenovirus-mediated gene transfer, recombinant adenovirus-induced tendon adhesion formation, BMP-12, bone morphogenetic protein-2 gene transfer, growth and differentiation factor-5 (GDF-5), and insulin like growth factor (IFG).

### Claim 22 (depends on 1)

The prosthetic stabilizing device of claim 1, wherein the lining material is loaded with at least one of hematopoietic stem cells and hematopoietic stem cells progenitors.

### Claim 23

A prosthetic stabilizing device for use with a knee replacement prosthesis that includes a tibial component adapted to be mounted to a patient's tibia and a femoral component adapted to be mounted to the patient's femur, where the tibial component interfaces with the femoral component to simulate the biomechanics of a knee joint, the stabilizing device comprising:
a first lining adapted to be mounted to at least one of a tibial component and a femoral component so that the first lining is positioned between the tibial component and the femoral component approximate a prosthetic intercondylar channel to supplement periarticular stability between the tibial component and the femoral component; and
a second lining adapted to be mounted to at least the other of the tibial component and the femoral component so that the second lining is positioned between the tibial component and the femoral component approximate the prosthetic intercondylar channel to supplement periarticular stability of the tibial component and the femoral component;
the first lining being comprised of a first lining material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials; and
the second lining being comprised of a second lining material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 24 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein:
the first lining includes at least one fastener comprised of a first fastener material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials; and
the second lining includes at least one fastener comprised of a second fastener material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 25 (depends on 24)

The prosthetic stabilizing device of claim 24, wherein the fastener material includes at least one, or an equivalent, of:
a poly-L-lactic acid material; and
collagen.

### Claim 26 (depends on 25)

The prosthetic stabilizing device of claim 25, wherein the fasteners are taken from a group consisting of:
screws;
snaps;
clips;
keyways; and
rivets.

### Claim 27 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein the lining material includes at least one, or an equivalent, of:
extra cellular matrices (ECMs);
poliglecaprone 25;
polydioxanone;
surgical gut suture (SGS);
gut;
polyglactin 910;
human autograft tendon material;
collagen fiber;
poly-L-lactic acid (PLLA);
polylactic acid (PLA);
polylactides (Pla);
racemic form of polylactide (D,L-Pla);
poly(L-lactide-co-D,L-lactide);
polyglycolides (PGa);
polyglycolic acid (PGA);
polycaprolactone (PCL);
polydioxanone (PDS);
polyhydroxyacids; and
resorbable plate material.

### Claim 28 (depends on 27)

The prosthetic stabilizing device of claim 27, wherein the extra cellular matrices (ECMs) includes at least one, or an equivalent, of:
porcine small intestine submucosa (SIS);
xenogeneic small intestine submucosa (xSIS);
urinary bladder submucosa (UBS);
laminated intestinal submucosa; and
glutaraldehyde-treated bovine pericardium (GLBP).

### Claim 29 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein the lining material is adapted to be substantially absorbed by a patient's body after implantation and to be substantially replaced by the patient's tissue.

### Claim 30 (depends on 29)

The prosthetic stabilizing device of claim 29, wherein the lining material is adapted to be substantially absorbed and replaced by the patient's tissue within approximately 6 months after implantation.

### Claim 31 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein:
the first lining is mounted to the tibial component and the second lining is mounted to the femoral component; and
the first lining mounted to the tibial component includes an outer surface that approximates a first contour potentially coming into contact therewith, the first contour being that of at least one of the femoral component and the second lining.

### Claim 32 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein:
the second lining is mounted to the tibial component and the first lining is mounted to the femoral component; and
the second lining mounted to the tibial component includes an outer surface that approximates a first contour potentially coming into contact therewith, the first contour being that of at least one of the femoral component and the first lining.

### Claim 33 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein at least one of the first lining material and the second lining material is loaded with at least one of a tissue promotion agent, a clotting agent, and an antibiotic agent.

### Claim 34 (depends on 33)

The prosthetic stabilizing device of claim 33, wherein at least one of the first lining material and the second lining material is loaded with a clotting agent that includes concentrated platelets.

### Claim 35 (depends on 33)

The prosthetic stabilizing device of claim 33, wherein at least one of the first lining material and the second lining material is loaded with an antibiotic agent that includes gentamicin.

### Claim 36 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein at least one of the first lining material and the second lining material is loaded with at least one of connective tissue stem cells and connective tissue stem cell progenitors.

### Claim 37 (depends on 36)

The prosthetic stabilizing device of claim 36, wherein the connective tissue stem cells and connective tissue stem progenitors are taken from the group consisting of: fibroblastic colony-forming cells, fibroplast colony-forming units (CFU-F), bone marrow stromal cells, mesenchymal stem cells (MSC), and vascular pericytes.

### Claim 38 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein at least one of the first lining material and the second lining material is loaded with a growth stimulating factor.

### Claim 39 (depends on 38)

The prosthetic stabilizing device of claim 38, wherein the growth stimulating factor is taken from the group consisting of: growth factor beta (GFB-β), basic fibroblast growth factor (bFGF), fibroblast growth factor (FGF), epidermal growth factor (EFG), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), direct-mediated gene transfer, fibroblast-mediated gene transfer, myoblast-mediated gene transfer, TGF-β gene family, adenovirus-mediated gene transfer, recombinant adenovirus-induced tendon adhesion formation, BMP-12, bone morphogenetic protein-2 gene transfer, growth and differentiation factor-5 (GDF-5), and insulin like growth factor (IFG).

### Claim 40 (depends on 23)

The prosthetic stabilizing device of claim 23, wherein at least one of the first lining material and the second lining material is loaded with at least one of hematopoietic stem cells and hematopoietic stem cells progenitors.

### Claim 41

A knee prosthesis comprising:
a tibial component adapted to be mounted to a patient's tibia;
a femoral component adapted to be mounted to a patient's femur, and to be pivotally coupled to the tibial component to form a prosthetic knee joint; and
a lining adapted to be mounted to at least one of the tibial component and the femoral component in the prosthetic knee joint so that the lining is positioned between the tibial component and the femoral component approximate a prosthetic intercondylar channel of the femoral component to supplement periarticular stability between the tibial component and the femoral component; and
the lining being comprised of a lining material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 42 (depends on 41)

The knee prosthesis of claim 41, further comprising at least one fastener for mounting the lining to one of the tibial component and the femoral component, wherein the fasteners are comprised of a fastener material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 43 (depends on 42)

The knee prosthesis of claim 42, wherein the fastener material includes at least one, or an equivalent, of:
a poly-L-lactic acid material; and
collagen.

### Claim 44 (depends on 42)

The knee prosthesis of claim 42, wherein the fasteners are taken from a group consisting of:
screws;
snaps;
clips;
keyways; and
rivets.

### Claim 45 (depends on 41)

The knee prosthesis of claim 41, wherein the lining material includes at least one, or an equivalent, of:
extra cellular matrices (ECMs);
poliglecaprone 25;
polydioxanone;
surgical gut suture (SGS);
gut;
polyglactin 910;
human autograft tendon material;
collagen fiber;
poly-L-lactic acid (PLLA);
polylactic acid (PLA);
polylactides (Pla);
racemic form of polylactide (D,L-Pla);
poly(L-lactide-co-D,L-lactide);
polyglycolides (PGa);
polyglycolic acid (PGA);
polycaprolactone (PCL);
polydioxanone (PDS);
polyhydroxyacids; and
resorbable plate material.

### Claim 46 (depends on 45)

The knee prosthesis of claim 45, wherein the extra cellular matrices (ECMs) includes at least one, or an equivalent, of:
porcine small intestine submucosa (SIS);
xenogeneic small intestine submucosa (xSIS);
urinary bladder submucosa (UBS);
laminated intestinal submucosa; and
glutaraldehyde-treated bovine pericardium (GLBP).

### Claim 47 (depends on 41)

The knee prosthesis of claim 41, wherein the lining material is adapted to be substantially absorbed by a patient's body after implantation and to be substantially replaced by the patient's tissue.

### Claim 48 (depends on 47)

The knee prosthesis of claim 47, wherein the lining material is adapted to be substantially absorbed and replaced by the patient's tissue within approximately 6 months after implantation.

### Claim 49 (depends on 41)

The knee prosthesis of claim 41, wherein at least one surface of the lining approximates a contour of a surface of at least one of the tibial component and the femoral component to which the lining is mounted.

### Claim 50 (depends on 41)

The knee prosthesis of claim 41, wherein at least a portion of the lining is adaptable to the topography of at least one of the tibial component and the femoral component to which the lining is mounted.

### Claim 51 (depends on 41)

The knee prosthesis of claim 41, wherein the lining is mounted to the tibial component and includes an outer surface that approximates a contour of a surface of the femoral component most likely coming into contact therewith.

### Claim 52 (depends on 51)

The knee prosthesis of claim 51, wherein the contour of an outer surface of the femoral component approximates an inner surface of at least one of a prosthetic medial condyle element and a prosthetic lateral condyle element partially defining the prosthetic intercondylar channel.

### Claim 53 (depends on 41)

The knee prosthesis of claim 41, wherein the lining is mounted to the femoral component and includes an outer surface that approximates a contour of a surface of the tibial component passing into the prosthetic intercondylar channel.

### Claim 54 (depends on 41)

The knee prosthesis of claim 41, wherein the lining material is loaded with at least one of a tissue promotion agent, a clotting agent, and an antibiotic agent.

### Claim 55 (depends on 54)

The knee prosthesis of claim 54, wherein the lining material is loaded with a clotting agent that includes concentrated platelets.

### Claim 56 (depends on 54)

The knee prosthesis of claim 54, wherein the lining material is loaded with an antibiotic agent that includes gentamicin.

### Claim 57 (depends on 41)

The knee prosthesis of claim 41, wherein:
the tibial component includes a stabilizing post at its proximal end adapted to be received within the intercondylar channel of the femoral component; and
the lining is adapted to be mounted to at least one of the stabilizing post and a surface of the intercondylar channel.

### Claim 58 (depends on 41)

The knee prosthesis of claim 41, wherein the lining material is loaded with at least one of connective tissue stem cells and connective tissue stem cell progenitors.

### Claim 59 (depends on 58)

The knee prosthesis of claim 58, wherein the connective tissue stem cells and connective tissue stem progenitors are taken from the group consisting of: fibroblastic colony-forming cells, fibroplast colony-forming units (CFU-F), bone marrow stromal cells, mesenchymal stem cells (MSC), and vascular pericytes.

### Claim 60 (depends on 41)

The knee prosthesis of claim 41, wherein the lining material is loaded with a growth stimulating factor.

### Claim 61 (depends on 60)

The knee prosthesis of claim 60, wherein the growth stimulating factor is taken from the group consisting of: growth factor beta (GFB-β), basic fibroblast growth factor (bFGF), fibroblast growth factor (FGF), epidermal growth factor (EFG), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), direct-mediated gene transfer, fibroblast-mediated gene transfer, myoblast-mediated gene transfer, TGF-β gene family, adenovirus-mediated gene transfer, recombinant adenovirus-induced tendon adhesion formation, BMP-12, bone morphogenetic protein-2 gene transfer, growth and differentiation factor-5 (GDF-5), and insulin like growth factor (IFG).

### Claim 62 (depends on 41)

The knee prosthesis of claim 41, wherein the lining material is loaded with at least one of hematopoietic stem cells and hematopoietic stem cells progenitors.

### Claim 63

A knee prosthesis comprising:
a femoral component adapted to be mounted to a patient's femur;
a tibial component adapted to be mounted to the patient's tibia, the tibial component including a stabilizing post at its proximal end adapted to be received within a prosthetic intercondylar channel of the femoral component to form a prosthetic hinge-type joint coupling; and
a lining mounted to at least one of the stabilizing post and an inner surface of the femoral component at least partially defining the prosthetic intercondylar channel to, at least temporarily, supplement periarticular stability between the stabilizing post and the prosthetic intercondylar channel;
the lining being comprised of a lining material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 64 (depends on 63)

The knee prosthesis of claim 63, further comprising at least one fastener for mounting the lining to at least one of the stabilizing post of the tibial component and the inner surface of the femoral component at least partially defining the prosthetic intercondylar channel, wherein the fastener is comprised of a fastener material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 65 (depends on 63)

The knee prosthesis of claim 63, wherein the lining material includes at least one, or an equivalent, of:
extra cellular matrices (ECMs);
poliglecaprone 25;
polydioxanone;
surgical gut suture (SGS);
gut;
polyglactin 910;
human autograft tendon material;
collagen fiber;
poly-L-lactic acid (PLLA);
polylactic acid (PLA);
polylactides (Pla);
racemic form of polylactide (D,L-Pla);
poly(L-lactide-co-D,L-lactide);
polyglycolides (PGa);
polyglycolic acid (PGA);
polycaprolactone (PCL);
polydioxanone (PDS);
polyhydroxyacids; and
resorbable plate material.

### Claim 66 (depends on 65)

The knee prosthesis of claim 65, wherein the extra cellular matrices (ECMs) includes at least one of:
porcine small intestine submucosa (SIS);
xenogeneic small intestine submucosa (xSIS);
urinary bladder submucosa (UBS);
laminated intestinal submucosa; and
glutaraldehyde-treated bovine pericardium (GLBP).

### Claim 67 (depends on 63)

The knee prosthesis of claim 63, wherein the lining material is adapted to be substantially absorbed by a patient's body after implantation and to be substantially replaced by the patient's tissue.

### Claim 68 (depends on 67)

The knee prosthesis of claim 67, wherein the lining material is adapted to be substantially absorbed and replaced by the patient's tissue within approximately 6 months after implantation.

### Claim 69 (depends on 63)

The knee prosthesis of claim 63, wherein the lining material is loaded with at least one of a tissue promotion agent, a clotting agent, and an antibiotic agent.

### Claim 70 (depends on 69)

The knee prosthesis of claim 69, wherein the lining material is loaded with a clotting agent that includes concentrated platelets.

### Claim 71 (depends on 69)

The knee prosthesis of claim 69, wherein the lining material is loaded with an antibiotic agent that includes gentamicin.

### Claim 72 (depends on 63)

The knee prosthesis of claim 63, wherein the lining material is loaded with at least one of connective tissue stem cells and connective tissue stem cell progenitors.

### Claim 73 (depends on 72)

The knee prosthesis of claim 72, wherein the connective tissue stem cells and connective tissue stem progenitors are taken from the group consisting of: fibroblastic colony-forming cells, fibroplast colony-forming units (CFU-F), bone marrow stromal cells, mesenchymal stem cells (MSC), and vascular pericytes.

### Claim 74 (depends on 63)

The knee prosthesis of claim 63, wherein the lining material is loaded with a growth stimulating factor.

### Claim 75 (depends on 74)

The knee prosthesis of claim 74, wherein the growth stimulating factor is taken from the group consisting of: growth factor beta (GFB-β), basic fibroblast growth factor (bFGF), fibroblast growth factor (FGF), epidermal growth factor (EFG), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), direct-mediated gene transfer, fibroblast-mediated gene transfer, myoblast-mediated gene transfer, TGF-β gene family, adenovirus-mediated gene transfer, recombinant adenovirus-induced tendon adhesion formation, BMP-12, bone morphogenetic protein-2 gene transfer, growth and differentiation factor-5 (GDF-5), and insulin like growth factor (IFG).

### Claim 76 (depends on 63)

The knee prosthesis of claim 63, wherein the lining material is loaded with at least one of hematopoietic stem cells and hematopoietic stem cells progenitors.

### Claim 77

A stabilizing device for use with a joint reconstruction surgical procedure, where the reconstructed joint includes an interface between at least two bones exhibiting biomechanics of a joint, the stabilizing device comprising:
a lining adapted to be mounted to at least one of a first bone and a second bone so that the lining is positioned between an interface of the first bone and the second bone to assist in maintaining the stability and functionality of a joint formed at least in part by the interface of the first and second bone; and
the lining comprises a lining material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 78 (depends on 77)

The stabilizing device of claim 77, further comprising at least one fastener for mounting the lining to at least one of the first bone and the second bone, wherein the fasteners are comprised of a fastener material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 79 (depends on 78)

The stabilizing device of claim 78, wherein the fastener material includes at least one, or an equivalent, of:
a poly-L-lactic acid material; and
collagen

### Claim 80 (depends on 78)

The stabilizing device of claim 78, wherein the fasteners are taken from a group consisting of:
screws;
snaps;
clips;
keyways; and
rivets.

### Claim 81 (depends on 77)

The stabilizing device of claim 77, wherein the lining material includes at least one, or an equivalent, of:
extra cellular matrices (ECMs);
poliglecaprone 25;
polydioxanone;
surgical gut suture (SGS);
gut;
polyglactin 910;
human autograft tendon material;
collagen fiber;
poly-L-lactic acid (PLLA);
polylactic acid (PLA);
polylactides (Pla);
racemic form of polylactide (D,L-Pla);
poly(L-lactide-co-D,L-lactide);
polyglycolides (PGa);
polyglycolic acid (PGA);
polycaprolactone (PCL);
polydioxanone (PDS);
polyhydroxyacids; and
resorbable plate material.

### Claim 82 (depends on 77)

The stabilizing device of claim 77, wherein the lining material is adapted to be substantially absorbed by a patient's body after implantation and to be substantially replaced by the patient's tissue.

### Claim 83 (depends on 82)

The stabilizing device of claim 82, wherein the lining material is adapted to be substantially absorbed and replaced by the patient's tissue within approximately 6 months after implantation.

### Claim 84 (depends on 77)

The stabilizing device of claim 77, wherein at least one of the first lining material and the second lining material is loaded with at least one of a tissue promotion agent, a clotting agent, and an antibiotic agent.

### Claim 85 (depends on 84)

The stabilizing device of claim 84, wherein the lining material is loaded with a clotting agent that includes concentrated platelets.

### Claim 86 (depends on 84)

The stabilizing device of claim 84, wherein the lining material is loaded with an antibiotic agent that includes gentamicin.

### Claim 87 (depends on 77)

The stabilizing device of claim 77, wherein the lining material is loaded with at least one of connective tissue stem cells and connective tissue stem cell progenitors.

### Claim 88 (depends on 87)

The stabilizing device of claim 87, wherein the connective tissue stem cells and connective tissue stem progenitors are taken from the group consisting of: fibroblastic colony-forming cells, fibroplast colony-forming units (CFU-F), bone marrow stromal cells, mesenchymal stem cells (MSC), and vascular pericytes.

### Claim 89 (depends on 77)

The stabilizing device of claim 77, wherein the lining material is loaded with a growth stimulating factor.

### Claim 90 (depends on 89)

The stabilizing device of claim 89, wherein the growth stimulating factor is taken from the group consisting of: growth factor beta (GFB-β), basic fibroblast growth factor (bFGF), fibroblast growth factor (FGF), epidermal growth factor (EFG), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), direct-mediated gene transfer, fibroblast-mediated gene transfer, myoblast-mediated gene transfer, TGF-β gene family, adenovirus-mediated gene transfer, recombinant adenovirus-induced tendon adhesion formation, BMP-12, bone morphogenetic protein-2 gene transfer, growth and differentiation factor-5 (GDF-5), and insulin like growth factor (IFG).

### Claim 91 (depends on 77)

The stabilizing device of claim 77, wherein the lining material is loaded with at least one of hematopoietic stem cells and hematopoietic stem cells progenitors.

### Claim 92

A method for providing at least temporary stability to a prosthetic knee joint which includes a tibial component interfacing a femoral component, the tibial and femoral components simulating at least certain biomechanics of a knee joint, the method comprising the step of:
mounting a stabilizing device to at least one of the femoral component and the tibial component to improve periarticular stability to a prosthetic knee joint, wherein the stabilizing device is comprised of a material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 93 (depends on 92)

The method of claim 92, wherein the mounting step includes the step of fastening the stabilizing device to at least one of the femoral component and the tibial component with a fastener comprised of a material selected from the group consisting of a biologic material, a biologically reabsorbable material, and a combination of biologic and biologically reabsorbable materials.

### Claim 94 (depends on 93)

The method of claim 93, wherein the fastener is taken from a group consisting of:
screws;
snaps;
clips;
keyways; and
rivets.

### Claim 95 (depends on 92)

The method of claim 92, wherein the material includes at least one of a tissue formation promotion agent, a clotting agent, and an antibacterial agent.

### Claim 96 (depends on 95)

The method of claim 95, wherein the material is adapted to be substantially absorbed by a patient's body after the mounting step and to be substantially replaced by the patient's tissue.

### Claim 97 (depends on 96)

The method of claim 96, wherein the material is adapted to be substantially absorbed and replaced by the patient's tissue within approximately 6 months after implantation.

### Claim 98 (depends on 92)

The method of claim 92, wherein the stabilizing device is contoured on at least one external surface to approximate the contour of the other one of the tibial component surface and the femoral component surface to which the device is mounted.

### Claim 99 (depends on 92)

The method of claim 92, wherein the stabilizing device is adaptable to be contoured to approximate the contour of at least the one of the tibial component surface and the femoral component surface to which the device is mounted.

### Claim 100 (depends on 92)

The method of claim 92, wherein the material is loaded with at least one of connective tissue stem cells and connective tissue stem cell progenitors.

### Claim 101 (depends on 100)

The method of claim 100, wherein the connective tissue stem cells and connective tissue stem progenitors are taken from the group consisting of: fibroblastic colony-forming cells, fibroplast colony-forming units (CFU-F), bone marrow stromal cells, mesenchymal stem cells (MSC), and vascular pericytes.

### Claim 102 (depends on 92)

The method of claim 92, wherein the material is loaded with a growth stimulating factor.

### Claim 103 (depends on 102)

The method of claim 102, wherein the growth stimulating factor is taken from the group consisting of: growth factor beta (GFB-β), basic fibroblast growth factor (bFGF), fibroblast growth factor (FGF), epidermal growth factor (EFG), transforming growth factor-β1 (TGF-β1), vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), direct-mediated gene transfer, fibroblast-mediated gene transfer, myoblast-mediated gene transfer, TGF-β gene family, adenovirus-mediated gene transfer, recombinant adenovirus-induced tendon adhesion formation, BMP-12, bone morphogenetic protein-2 gene transfer, growth and differentiation factor-5 (GDF-5), and insulin like growth factor (IFG).

### Claim 104 (depends on 92)

The method of claim 92, wherein the material is loaded with at least one of hematopoietic stem cells and hematopoietic stem cells progenitors.

### Claim 105

A knee prosthesis comprising:
a tibial component adapted to be mounted to a patient's tibia;
a femoral component adapted to be mounted to a patient's femur, and to be pivotally coupled to the tibial component to form a prosthetic knee joint; and
a lining being selectively attachable to at least one of the tibial component and the femoral component in the prosthetic knee joint so that the lining is adapted to be mounted between the tibial component and the femoral component approximate a prosthetic intercondylar channel of the femoral component to supplement periarticular stability between the tibial component and the femoral component, whereby repositioning or degradation of the liner does not appreciably hinder the functionality of the femoral component and the tibial component.
